Cover Image

Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Peptides

Abstract

Product Description

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer

The pancreatic cancer report part comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.

Part II: Cancer Vaccines

The cancer vaccine report part comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. This part extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications.

Part III: Peptides

The cancer peptide drug report part comprises defined and up to date development strategies for 152 peptide drugs in oncology within the portfolio of 104 companies world-wide, from Ceased to Marketed. The report extensively analyses their 123 identified drug targets, organized into 103 drug target strategies, and assesses them in 56 cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Table of Contents

Key Topics Covered:

Part I: Pancreatic Cancer

  • 5.1 The Scope of this Report
  • 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (171 Drug Targets)
  • 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Pancreatic Cancer Therapeutic Pipeline? (142 Drug Target Strategies and 213 Drugs)
  • 8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Different Compound Strategies)
  • 9 Pipeline and Portfolio Planning: Competitive Benchmarking of Pancreatic Cancer Therapeutic Pipeline by Investigator (137 Investigators)
  • 11 Drug Index
  • 12 Company Index
  • Figures: Includes 5 Figures
  • Tables: Includes 193 Tables
  • Total Number of Pages: 610

Part II: Cancer Vaccines

  • 5.1 The Scope of this Report
  • 6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets)
  • 7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs)
  • 8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies)
  • 9 Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications)
  • 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators)
  • 11 Disclaimer
  • 12 Drug Index
  • 13 Company Index
  • Figures: Includes 6 Figures
  • Tables: Includes 205 Tables
  • Total Number of Pages: 659

Part III: Peptides

  • 5.1 The Scope of this Report
  • 6 Consider the Therapeutic Target Among Peptide Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (123 Drug Targets)
  • 7 Emerging New Products to Established Ones: Drug Target Strategies of Peptide Drugs in Oncology by their Highest Stage of Development (103 Drug Targets Strategies and 152 Peptide Drugs)
  • 8 Selecting Indication for Peptide Drugs in Oncology (56 Cancer Indications)
  • 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator (104 Investigators and 152 Peptide Drugs)
  • 10 Disclaimer
  • 11 Drug Index
  • 12 Company Index
  • Figures: Includes 5 Figures
  • Tables: Includes 207 Tables
  • Total Number of Pages: 906

Featured Companies

This Report Includes the Following Companies:

  • 7TM Pharma
  • Abbott
  • Abraxis BioScience
  • AC Immune
  • Acceleron Pharma
  • Active Biotech
  • Adaptimmune
  • Adherex
  • Aduro BioTech
  • Advantagene
  • Advaxis
  • AEgera
  • AEterna Zentaris
  • Affymax
  • Aida Pharmaceuticals
  • Aileron Therapeutics
  • Akela Pharma
  • Allostera
  • Allosterix
  • AlphaVax
  • Ambrilia Biopharma
  • Amgen
  • Anchor Therapeutics
  • AngioChem
  • Angstrom Pharmaceuticals
  • Antisense Pharma
  • AplaGen Biopharmaceuticals
  • ApopLogic Pharmaceuticals
  • Apotex
  • Apthera
  • Archer Biosciences
  • Ardana
  • Ariad
  • ArQule
  • Array BioPharma
  • Astellas
  • AstraZeneca
  • Attenuon
  • AVI BioPharma
  • Bavarian Nordic
  • Baxter International
  • Bayer
  • Bellicum Pharmaceuticals
  • Biogen Idec
  • Biokine Therapeutics
  • Bionovo
  • BioNumerik
  • Biostar
  • BioVex
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BTG
  • Cadila
  • CanBas
  • Cancer Advances
  • Cancer Innovations
  • Cancer Research Technology
  • CDG Therapeutics
  • Celecure
  • Cell Genesys
  • Cell Therapeutics
  • Celldex Therapeutics
  • Celsion
  • Celtic Pharma
  • Center of Molecular Immunology
  • Cephalon
  • CG Therapeutics
  • Chemokine Therapeutics
  • Cleveland BioLabs
  • Clinuvel
  • CompleGen
  • Compugen
  • Cornerstone Pharmaceuticals
  • Cosmo Pharmaceuticals
  • CSL
  • Curaxis
  • Cyclacel
  • Cynvec
  • CytImmune Sciences
  • Cytokinetics
  • Daiichi Sankyo
  • Dara Biosciences
  • Dendreon
  • DeveloGen
  • Diatos
  • Digna Biotech
  • Dongkook Pharm
  • EGEN Inc
  • Eisai
  • Elan
  • Eli Lilly
  • Endo Pharmaceuticals
  • Enkam Pharmaceuticals
  • EntreMed
  • Epeius Biotechnologies
  • EpiCept
  • Esperance Pharmaceuticals
  • Facet Biotech
  • FibroGen
  • Galena Biopharma
  • Generex
  • GenOdyssee Pharmaceuticals
  • GENova Biotherapeutics
  • Genovax
  • Genta
  • GENTICEL
  • GenVec
  • Genzyme
  • Geron
  • GlaxoSmithKline
  • Gliknik
  • GlobeImmune
  • Gloucester Pharmaceuticals
  • GlycoGenesys
  • GP Pharm
  • Gradalis
  • Gryphon Therapeutics
  • Hana Biosciences
  • Hoffmann-La Roche
  • Human Genome Sciences
  • Ichor Medical Systems
  • Idera Pharmaceuticals
  • ImmunoCellular Therapeutics
  • ImmunoFrontier
  • Immunomedics
  • Immunotope
  • ImmuPharma
  • Immutep
  • Innate Pharma
  • Innovive
  • Inovio
  • Introgen Therapeutics
  • Ipsen
  • ISA Pharmaceuticals
  • Johnson & Johnson
  • Karyon-CTT
  • Kyowa Hakko Kirin
  • Lee's Pharmaceutical
  • Marillion Pharmaceuticals
  • MBiotec
  • Meda
  • Medical Marketing International
  • MediGene
  • Mediolanum
  • Medisyn Technologies
  • Menarini
  • Merck & Co
  • Merck KGaA
  • MethylGene
  • Micromet
  • MolMed
  • Mologen
  • Nektar Therapeutics
  • Nemod Biotherapeutics
  • NeoPharm
  • Neovacs
  • Neurobiological Technologies
  • Nidus Laboratories
  • Nippon Kayaku
  • Nippon Shinyaku
  • Non-industrial source
  • Northwest Biotherapeutics
  • Novacea
  • Novartis
  • NovaRx
  • Novogen
  • NPS Pharmaceuticals
  • OncoMune
  • OncoTherapy Science
  • Oncothyreon
  • Oncovir
  • Onyvax
  • OSI Pharmaceuticals
  • Oxford BioMedica
  • OXiGENE
  • Paladin Labs
  • PanaGin
  • Patrys
  • Pepscan Systems
  • Pepscan Therapeutics
  • Peptagen
  • PepTx
  • Pfizer
  • Pharmacyclics
  • PharmaEngine
  • PharmaGap
  • PharmaMar
  • Pharmexa
  • Pierre Fabre
  • Piramal
  • Prima Biomed
  • Pro-Pharmaceuticals
  • Progenics Pharmaceuticals
  • Protagonist
  • Protherics
  • Q Chip
  • QLT
  • Radient Pharmaceuticals
  • Raptor Pharmaceutical
  • Reata Pharmaceuticals
  • Receptor BioLogix
  • Regeneron
  • Regulon
  • responsif
  • RESprotect
  • Rexahn
  • Samyang
  • Sanofi-Aventis
  • Santaris Pharma
  • Scancell
  • SciClone Pharmaceuticals
  • Serometrix
  • Shire
  • Soligenix
  • Spectrum Pharmaceuticals
  • SuperGen
  • Taiho
  • Takeda
  • TapImmune
  • Tau Therapeutics
  • Thallion Pharmaceuticals
  • Therion Biologics
  • Theryte
  • Tigris Pharmaceuticals
  • Titan Pharmaceuticals
  • TopoTarget
  • Tragara Pharmaceuticals
  • Transgene
  • Trion Pharma
  • Unigene
  • United Biomedical
  • Vaccinex
  • Vaxil BioTherapeutics
  • Vaxon Biotech
  • VaxOnco
  • Vectura
  • Vertex Pharmaceuticals
  • Vical
  • Wilex
  • Vion Pharmaceuticals
  • VioQuest
  • Viragen
  • Virionics
  • ViroMed
  • Xerion
  • Xigen
  • Yakult Honsha
  • YM BioSciences
  • Zelos Therapeutics
  • Zensun
  • Zhejiang Beta Pharma

Featured Drugs

A Shortlist of Drugs Included are:

  • A6
  • abarelix
  • ABT-510
  • ADXS11-001
  • AE-37
  • AEZS-108
  • afamelanotide
  • aflibercept
  • ALVAC-CEA/B7.1
  • angiopep+paclitaxel
  • astuprotimut-r
  • AVX-701
  • belagenpumatucel-L
  • bevacizumab
  • BP-GMAX-CD1
  • brivudine
  • Cadi-05
  • capecitabine
  • catumaxomab
  • CB-10-01
  • CBP-501
  • CEA-TRICOM
  • cetuximab
  • CG-201
  • CMLVAX-100
  • corticorelin acetate
  • CTL901
  • CTP-37
  • CVac
  • DCVax-prostate
  • deslorelin
  • E-75
  • emepepimut-S
  • erlotinib
  • everolimus
  • fowlpox-PSA vaccine
  • golnerminogene pradenovec
  • goserelin
  • GRNVAC1
  • GV-1001
  • GV-1002
  • GVAX
  • GVX-3322
  • GX-301
  • Her-2/Neu peptides
  • histrelin
  • IGN-101
  • imMucin
  • ImmunoVEX tri-melan
  • IMO-2055
  • INGN-225
  • IPP-204106
  • ISA-P53-01
  • larotaxel
  • leuprolide
  • leuprolide acetate
  • MAGE-3-TK
  • masitinib
  • MDX-1379
  • ME-103
  • MGN-1601
  • MSI vaccine
  • MVA-BN
  • MVA-BN Her-2 vaccine
  • nadroparin
  • NAFB001
  • netupitant
  • nimotuzumab
  • Norelin
  • Onyvax-105
  • OTS-102
  • ozarelix
  • paclitaxel
  • PANVAC-VF
  • pasireotide
  • pasireotide LAR
  • pDOM-PSMA27
  • PEP-223
  • poly-ICLC
  • PR1:169-177 peptide
  • PROSTVAC
  • PX-104.1
  • Reximmune-C
  • rindopepimut
  • romurtide
  • SAI-EGF
  • sotatercept
  • Stimuvax
  • sunitinib malate
  • tegafur + uracil
  • TG-4001
  • TG-4010
  • thymalfasin
  • tigapotide triflutate
  • TM-30339
  • TroVax
  • TS-1
  • verpasep caltespen
  • VX-001
  • ZYC-300
Show More
Pricing
Get Notified
Email me when related reports are published